Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer

Table 2 Significant associations of mutations and amplifications with drug response in HNSCC cell lines

Drug	Gene	Comparison	p	LFDR	Mean WT/NA log₂(IC50(μM))	Mut/Amp log₂(IC50(μM))	Effect Log2(IC50(μM)) [95% CI]
ATRA	TP53	wild-type vs mutant	<0.001	0.0069	9.96	7.15	2.81 [1.82-3.79]
AZD6482	PIK3CA	wild-type vs mutant	<0.001	0.023	4.87	0.689	4.18 [2.73-5.63]
JNK Inhibitor VIII	EGFR	non-amplified vs. amplified	<0.001	0.056	8.31	5.96	2.34 [1.49-3.20]
AZD6482	EGFR	non-amplified vs. amplified	<0.001	0.056	4.83	1.11	3.72 [2.17-5.26]
PF-562271	PIK3CA	wild-type vs mutant	<0.001	0.079	2.88	0.379	2.50 [1.55-3.46]

Legend: p – p value testing interaction, LFDR - local false discovery rate, WT - wild-type, NA - non-amplified, Mut – mutation, Amp – amplified, CI - confidence interval.

ISSN: 2050-6511